Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion

Akira Kisanuki, Douglas S. Segar, Thomas Ryan, Michael Johnson, Chuwa Tei, Harvey Feigenbaum, Stephen Sawada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

At low doses, dobutamine has potent inotropic, but limited chronotropic, effects - properties that may be necessary for detection of hibernating myocardium. The efficacy of other catecholamines, which have more closely coupled inotropic and chronotropic effects, for the detection of viable myocardium is unknown. This study evaluated the efficacy of arbutamine, a catecholamine with potent chrono-tropic effects, for the detection of viable myocardium in a canine model of hibernating myocardium. Contractile reserve was assessed during stepwise arbutamine infusion (dosages of 2.5, 5, 10, 50, and 100 ng/kg/min) at 3 days (early) and 4 weeks (late) after coronary ligation. Segment shortening, wall thickening, and segmental wall motion were assessed by sonomicrometry and echocardiography. After 4 weeks of occlusion, functional recovery was assessed after revascularization. During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia. The sensitivity was 50% for segment shortening, 20% for wall thickening, and 75% for wall motion score. The late arbutamine study had improved sensitivity. The sensitivity was 100% for segment shortening, 80% for wall thickening, and 90% for wall motion score at a dosage of 50 ng/kg/ min. At the late arbutamine study, myocardial perfusion reserve in the ischemic zone of dogs with functional recovery was only mildly reduced (2.0 versus 2.6 in nonischemic zones, P = .53). After coronary occlusion, viable myocardium can be detected with high doses of arbutamine that produce tachycardia. However, the sensitivity of arbutamine stimulation for predicting functional recovery is low early after occlusion, but it is improved by 4 weeks after occlusion with adequate perfusion reserve.

Original languageEnglish
Pages (from-to)138-148
Number of pages11
JournalJournal of the American Society of Echocardiography
Volume14
Issue number2
StatePublished - 2001

Fingerprint

Coronary Occlusion
Myocardium
Tachycardia
Catecholamines
Perfusion
Dobutamine
arbutamine
Ligation
Echocardiography
Canidae
Dogs

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion. / Kisanuki, Akira; Segar, Douglas S.; Ryan, Thomas; Johnson, Michael; Tei, Chuwa; Feigenbaum, Harvey; Sawada, Stephen.

In: Journal of the American Society of Echocardiography, Vol. 14, No. 2, 2001, p. 138-148.

Research output: Contribution to journalArticle

Kisanuki, Akira ; Segar, Douglas S. ; Ryan, Thomas ; Johnson, Michael ; Tei, Chuwa ; Feigenbaum, Harvey ; Sawada, Stephen. / Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion. In: Journal of the American Society of Echocardiography. 2001 ; Vol. 14, No. 2. pp. 138-148.
@article{25c765ec6a1e4e1e8043cdf770faf438,
title = "Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion",
abstract = "At low doses, dobutamine has potent inotropic, but limited chronotropic, effects - properties that may be necessary for detection of hibernating myocardium. The efficacy of other catecholamines, which have more closely coupled inotropic and chronotropic effects, for the detection of viable myocardium is unknown. This study evaluated the efficacy of arbutamine, a catecholamine with potent chrono-tropic effects, for the detection of viable myocardium in a canine model of hibernating myocardium. Contractile reserve was assessed during stepwise arbutamine infusion (dosages of 2.5, 5, 10, 50, and 100 ng/kg/min) at 3 days (early) and 4 weeks (late) after coronary ligation. Segment shortening, wall thickening, and segmental wall motion were assessed by sonomicrometry and echocardiography. After 4 weeks of occlusion, functional recovery was assessed after revascularization. During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia. The sensitivity was 50{\%} for segment shortening, 20{\%} for wall thickening, and 75{\%} for wall motion score. The late arbutamine study had improved sensitivity. The sensitivity was 100{\%} for segment shortening, 80{\%} for wall thickening, and 90{\%} for wall motion score at a dosage of 50 ng/kg/ min. At the late arbutamine study, myocardial perfusion reserve in the ischemic zone of dogs with functional recovery was only mildly reduced (2.0 versus 2.6 in nonischemic zones, P = .53). After coronary occlusion, viable myocardium can be detected with high doses of arbutamine that produce tachycardia. However, the sensitivity of arbutamine stimulation for predicting functional recovery is low early after occlusion, but it is improved by 4 weeks after occlusion with adequate perfusion reserve.",
author = "Akira Kisanuki and Segar, {Douglas S.} and Thomas Ryan and Michael Johnson and Chuwa Tei and Harvey Feigenbaum and Stephen Sawada",
year = "2001",
language = "English",
volume = "14",
pages = "138--148",
journal = "Journal of the American Society of Echocardiography",
issn = "0894-7317",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Arbutamine stimulation detects viable myocardium 4 weeks after coronary occlusion

AU - Kisanuki, Akira

AU - Segar, Douglas S.

AU - Ryan, Thomas

AU - Johnson, Michael

AU - Tei, Chuwa

AU - Feigenbaum, Harvey

AU - Sawada, Stephen

PY - 2001

Y1 - 2001

N2 - At low doses, dobutamine has potent inotropic, but limited chronotropic, effects - properties that may be necessary for detection of hibernating myocardium. The efficacy of other catecholamines, which have more closely coupled inotropic and chronotropic effects, for the detection of viable myocardium is unknown. This study evaluated the efficacy of arbutamine, a catecholamine with potent chrono-tropic effects, for the detection of viable myocardium in a canine model of hibernating myocardium. Contractile reserve was assessed during stepwise arbutamine infusion (dosages of 2.5, 5, 10, 50, and 100 ng/kg/min) at 3 days (early) and 4 weeks (late) after coronary ligation. Segment shortening, wall thickening, and segmental wall motion were assessed by sonomicrometry and echocardiography. After 4 weeks of occlusion, functional recovery was assessed after revascularization. During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia. The sensitivity was 50% for segment shortening, 20% for wall thickening, and 75% for wall motion score. The late arbutamine study had improved sensitivity. The sensitivity was 100% for segment shortening, 80% for wall thickening, and 90% for wall motion score at a dosage of 50 ng/kg/ min. At the late arbutamine study, myocardial perfusion reserve in the ischemic zone of dogs with functional recovery was only mildly reduced (2.0 versus 2.6 in nonischemic zones, P = .53). After coronary occlusion, viable myocardium can be detected with high doses of arbutamine that produce tachycardia. However, the sensitivity of arbutamine stimulation for predicting functional recovery is low early after occlusion, but it is improved by 4 weeks after occlusion with adequate perfusion reserve.

AB - At low doses, dobutamine has potent inotropic, but limited chronotropic, effects - properties that may be necessary for detection of hibernating myocardium. The efficacy of other catecholamines, which have more closely coupled inotropic and chronotropic effects, for the detection of viable myocardium is unknown. This study evaluated the efficacy of arbutamine, a catecholamine with potent chrono-tropic effects, for the detection of viable myocardium in a canine model of hibernating myocardium. Contractile reserve was assessed during stepwise arbutamine infusion (dosages of 2.5, 5, 10, 50, and 100 ng/kg/min) at 3 days (early) and 4 weeks (late) after coronary ligation. Segment shortening, wall thickening, and segmental wall motion were assessed by sonomicrometry and echocardiography. After 4 weeks of occlusion, functional recovery was assessed after revascularization. During the early arbutamine study, the sensitivity for predicting functional recovery was highest at a dosage of 50 ng/kg/min, which also produced tachycardia. The sensitivity was 50% for segment shortening, 20% for wall thickening, and 75% for wall motion score. The late arbutamine study had improved sensitivity. The sensitivity was 100% for segment shortening, 80% for wall thickening, and 90% for wall motion score at a dosage of 50 ng/kg/ min. At the late arbutamine study, myocardial perfusion reserve in the ischemic zone of dogs with functional recovery was only mildly reduced (2.0 versus 2.6 in nonischemic zones, P = .53). After coronary occlusion, viable myocardium can be detected with high doses of arbutamine that produce tachycardia. However, the sensitivity of arbutamine stimulation for predicting functional recovery is low early after occlusion, but it is improved by 4 weeks after occlusion with adequate perfusion reserve.

UR - http://www.scopus.com/inward/record.url?scp=0035138866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035138866&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 138

EP - 148

JO - Journal of the American Society of Echocardiography

JF - Journal of the American Society of Echocardiography

SN - 0894-7317

IS - 2

ER -